Entrada Therapeutics, Inc.
No enriched coverage for $TRDA in the last 7 days.
MPM BIOVENTURES 2018, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
MPM BioVentures 2014, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
MPM BIOVENTURES 2018, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
In the last 30 days, TRDA insiders filed 24 SEC Form 4 transactions — no purchases and 24 sales ($7.2M). The most active reporter was MPM BIOVENTURES 2018, L.P. with 12 filings.
Insider sale by a 10% owner may signal reduced confidence, but size is modest.
Insider sale suggests possible downside pressure; size is modest for a micro‑cap.
The insider sale reduces insider ownership but the transaction size is modest relative to market cap.
This is an insider/affiliate open-market sale by a large 10% owner, which can modestly affect near-term sentiment but does not signal a fundamental change by itself.
Insider sale may signal lack of confidence, but size is modest.
AlphAI scores every news story that mentions TRDA with an AI model for sentiment and relevance, and aggregates insider trades from Entrada Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MPM BIOVENTURES 2018, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
1 min readMPM BioVentures 2014, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
1 min readMPM BIOVENTURES 2018, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
1 min readMPM BioVentures 2014, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
2 min readMPM BIOVENTURES 2018, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
1 min readMPM BioVentures 2014, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
1 min readMPM BioVentures 2014, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
1 min readMPM BIOVENTURES 2018, L.P. sold 62,714 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.36 ($7.06–$7.54, $0.46M total) across 3 trades over 2026-08-24 to 2026-08-26. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
1 min readPARMAR KUSH sold 155,255 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.95 ($6.85–$7.00, $1.08M total) across 3 trades over 2026-08-06 to 2026-08-10.
2 min read5AM Ventures V, L.P. sold 62,811 shares of Entrada Therapeutics, Inc. (TRDA) at an average of $6.88 ($6.85–$7.00, $0.43M total) across 2 trades over 2026-08-06 to 2026-08-07.
1 min read